IGC Pharma (IGC) Raw Materials (2019 - 2026)

IGC Pharma (IGC) has reported Raw Materials for 8 consecutive years, with $447000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Raw Materials fell 59.51% year-over-year to $447000.0 in Q1 2026; TTM through Mar 2026 was $447000.0, a 59.51% decrease from a year earlier, with the FY2026 full-year figure at $447000.0, down 59.51% from the prior year.
• Raw Materials was $447000.0 for Q1 2026 at IGC Pharma, roughly flat from $446000.0 in the prior quarter.
• Over five years, Raw Materials peaked at $3.0 million in Q4 2022 and troughed at $446000.0 in Q3 2025.
• A 5-year average of $1.5 million and a median of $1.1 million in 2024 frame the typical range for Raw Materials.
• Across the five-year window, Raw Materials jumped 30.5% in 2022 and sank 59.6% in 2025, its largest moves.
• Over 5 years, Raw Materials stood at $3.0 million in 2022, then plunged by 53.52% to $1.4 million in 2023, then declined by 24.4% to $1.1 million in 2024, then plunged by 58.28% to $446000.0 in 2025, then increased by 0.22% to $447000.0 in 2026.
• The last three Raw Materials figures came in at $447000.0 (Q1 2026), $446000.0 (Q4 2025), and $446000.0 (Q3 2025), per Business Quant data.